Teva Purinethol (correction)
Executive Summary
In a story on Purinethol (6-mercaptopurine) labeling, "The Pink Sheet" referred to the leukemia drug as a GlaxoSmithKline product ("The Pink Sheet" July 21, 2003, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding generics of Relafen (nabumetone) (1"The Pink Sheet" May 5, 2003, In Brief)...
You may also be interested in...
Teva/GSK settle Relafen litigation
All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.